Equities

Invizyne Technologies Inc

IZTC:NAQ

Invizyne Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.69
  • Today's Change0.19 / 1.31%
  • Shares traded93.97k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The Company's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The Company is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. It can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).

  • Revenue in USD (TTM)0.00
  • Net income in USD-5.12m
  • Incorporated2019
  • Employees31.00
  • Location
    Invizyne Technologies Inc750 Royal Oaks Drive, Suite 10MONROVIA 91016United StatesUSA
  • Phone+1 (626) 415-1488
  • Websitehttps://www.invizyne.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rani Therapeutics Holdings Inc0.00-28.17m109.36m140.00--35.26-----1.06-1.060.000.05790.00----0.00-96.37---165.17-------------16.570.8306-------11.06------
Alto Neuroscience Inc0.00-57.45m110.26m88.00--0.6683-----2.42-2.420.006.120.00----0.00-46.93---51.10--------------0.0649-------31.02------
Context Therapeutics Inc0.00-30.15m112.50m5.00--1.34-----0.9117-0.91170.001.120.00----0.00-55.16---58.90--------------0.00-------61.53------
CAMP4 Therapeutics Corp350.00k-49.71m112.74m58.00------322.11-2.55-2.550.01790.7707------5,468.75-------------14,203.71------0.0221-------11.54------
Lineage Cell Therapeutics Inc8.72m-20.11m113.30m75.00--1.71--12.99-0.1096-0.10960.04740.35050.086--20.83116,253.30-19.77-19.53-22.80-22.5995.0089.13-229.91-370.88----0.0021---39.1612.3918.22---27.16--
Invizyne Technologies Inc0.00-5.12m117.85m31.00---------0.6305-0.63050.00-0.44310.00----0.00-146.70-----------------66.29---------46.00------
Adverum Biotechnologies Inc1.00m-94.11m119.61m121.00--0.8299--119.61-6.03-6.030.05856.930.0046----8,264.46-43.66-36.39-50.24-39.04-----9,411.10-5,279.60----0.00----17.4324.18---0.0247--
Outlook Therapeutics Inc0.00-94.05m121.35m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
Ventyx Biosciences Inc0.00-152.52m122.33m75.00--0.4386-----2.37-2.370.003.940.00----0.00-48.98---52.21--------------0.00-------77.97------
Vigil Neuroscience Inc0.00-82.60m122.64m66.00--1.34-----2.07-2.070.002.230.00----0.00-56.88---66.15--------------0.00-------20.98------
Cidara Therapeutics Inc18.86m-123.53m122.96m69.00--1.06--6.52-26.06-25.943.7416.410.167--8.28273,304.30-109.42-65.23-169.41-154.3787.21---655.07-100.61----0.0055---0.8425--31.72--23.33--
Seres Therapeutics Inc64.00k-165.29m124.55m233.00--5.21--1,946.13-1.14-0.22710.00040.14050.0002----274.68-60.50-41.51-82.15-54.13-----258,259.40-170.14---20.450.00--1,672.2434.9154.54--32.72--
Pyxis Oncology Inc16.15m-57.36m124.88m54.00--0.8124--7.73-1.05-1.050.29772.590.0845----322,920.00-30.03---34.41--97.06---355.24------0.0008------38.87------
Repare Therapeutics Inc66.52m-84.05m126.26m179.00--0.7216--1.90-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
Skye Bioscience Inc0.00-21.24m126.51m11.00--1.67-----0.8405-0.84050.002.500.00----0.00-43.73-232.67-54.60--------------0.00-------93.23--23.38--
Data as of Nov 22 2024. Currency figures normalised to Invizyne Technologies Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.